Does Cigna Cover Vardenafil (Levitra/Staxyn)?

Cigna's Standard Coverage Policy for Vardenafil

Most Cigna commercial plans cover generic vardenafil for the FDA-approved indication of erectile dysfunction, subject to prior authorization and quantity limits. The drug earned FDA approval in 2003 based on key trials demonstrating that vardenafil 10 mg and 20 mg significantly improved erectile function versus placebo, with International Index of Erectile Function (IIEF) domain score improvements of 5.9 to 8.8 points 1. Cigna's pharmacy benefit management arm reviews ED medications under its Erectile Dysfunction Agents policy, which classifies PDE5 inhibitors as medically necessary when a diagnosis of organic or mixed erectile dysfunction is documented 2.

Coverage specifics vary by plan design. Employer-sponsored Cigna PPO and HMO plans each maintain their own formulary editions, meaning a drug's tier placement can shift between open-access and network plans. Self-funded employer groups sometimes exclude ED medications entirely, a carve-out that Cigna administers but does not control. Always confirm your specific plan's Summary of Benefits and Coverage (SBC) or call the member services number on your card before assuming a claim will process. Cigna's 2025 National Preferred Formulary does list generic vardenafil, but brand-name Levitra was removed from many Cigna preferred lists after generic entry in 2018 3.

Formulary Tier Placement and What It Means for Your Copay

Generic vardenafil typically lands on Cigna's Tier 2 (preferred brand) or Tier 3 (non-preferred brand) depending on the specific formulary edition your employer selected. Tier 2 copays on Cigna plans commonly range from $35 to $75 per fill. Tier 3 placement pushes that to $75 to $150. Brand Levitra, where still listed, usually occupies Tier 4 (specialty/non-preferred), with coinsurance of 25-50% after deductible.

Staxyn, the orally disintegrating tablet formulation, presents a separate challenge. Many Cigna formularies classify Staxyn as non-formulary, requiring a formulary exception request rather than a simple prior authorization 4. The ODT formulation showed bioequivalence to standard vardenafil tablets in pharmacokinetic studies, but Cigna does not always recognize formulation preference as sufficient medical justification. Your prescriber would need to document a clinical reason you cannot swallow standard tablets, such as dysphagia or post-surgical anatomy.

The price gap matters. Generic vardenafil carries a cash-pay average of $30 to $60 per month at retail pharmacies, compared with approximately $350 per month for brand Levitra 5. That generic discount is precisely why Cigna steers members toward the generic through tier differentials and step therapy.

Prior Authorization Requirements

Cigna rates vardenafil prior authorization difficulty as moderate. The prescriber must submit documentation confirming a diagnosis of erectile dysfunction, ideally with an ICD-10 code of N52.01 (erectile dysfunction due to arterial insufficiency), N52.9 (unspecified), or a related code. The PA request should include the following elements:

Clinical documentation needed: A history and physical documenting ED duration and severity, relevant comorbidities (diabetes, cardiovascular disease, hypertension), current medication list, and prior ED treatment attempts. The American Urological Association (AUA) guidelines recommend PDE5 inhibitors as first-line pharmacotherapy for ED, which supports the medical necessity argument 6.

Response timeline: Cigna standard PA decisions arrive within 5 business days for non-urgent requests and within 24 hours for urgent requests. An urgent designation applies when the prescriber attests that waiting would seriously jeopardize the member's health or ability to regain function.

Approval duration: PA approvals for vardenafil on Cigna plans typically last 12 months before requiring renewal. Some Cigna Medicare Advantage plans use shorter 6-month approval windows. A large meta-analysis of PDE5 inhibitor trials (N=3,725) confirmed sustained efficacy of vardenafil across 12 months of continuous use, supporting annual approval cycles 7.

Step Therapy: Will Cigna Make You Try Sildenafil First?

Yes, many Cigna commercial formularies enforce step therapy for vardenafil. The most common protocol requires a documented 30-day trial of sildenafil (generic Viagra) before Cigna will authorize vardenafil. Some plans also accept prior tadalafil use as meeting the step requirement. The rationale is straightforward cost management: generic sildenafil costs $3 to $15 per month at most pharmacies.

Step therapy can be bypassed. Your prescriber can request a step therapy exception if you have a documented contraindication to sildenafil, experienced adverse effects (visual disturbances, severe headache, flushing), or have a drug interaction that makes sildenafil unsafe. Vardenafil has a distinct pharmacokinetic profile with a half-life of 4 to 5 hours and slightly different selectivity among PDE isoenzymes compared with sildenafil 8. Clinically, Porst et al. demonstrated that vardenafil produced statistically significant improvements in IIEF erectile function domain scores as early as week 4 in men with moderate-to-severe ED, a finding relevant when arguing that switching agents may benefit non-responders 1.

A clinical exception letter should reference the specific adverse event, the date of the sildenafil trial, the dose attempted, and the published evidence supporting pharmacologic differences between PDE5 inhibitors. The Endocrine Society's 2018 guideline on testosterone therapy and ED management notes that "individual patient response to PDE5 inhibitors varies, and switching among agents is a reasonable clinical strategy when initial therapy fails or produces intolerable side effects" 9.

How to Appeal a Cigna Denial of Vardenafil

Cigna provides a structured appeal pathway with three levels. Denials for vardenafil most commonly occur because of missing documentation, failure to complete step therapy, or an excluded benefit under the employer's plan design.

Level 1: Internal appeal. You or your prescriber submit a written appeal within 180 days of the denial. Include updated clinical notes, a letter of medical necessity, and any supporting literature. Cigna assigns a physician reviewer who was not involved in the initial denial. Decisions take up to 30 calendar days for pre-service appeals and up to 60 days for post-service claims 10.

Level 2: Second internal appeal. If the first appeal is denied, you may request a second review. This is especially useful if you can provide additional documentation, such as results from a nocturnal penile tumescence test, penile Doppler ultrasound, or lab values (testosterone, prolactin, HbA1c) that strengthen the clinical case. Testosterone deficiency is a well-documented contributor to PDE5 inhibitor non-response, with a randomized trial by Spitzer et al. (N=140) showing that testosterone replacement improved sildenafil response rates from 54% to 73% in hypogonadal men 11.

Level 3: External independent review. After exhausting internal appeals, you can request an external review by an independent review organization (IRO). The IRO decision is binding on Cigna. State insurance departments regulate this process, and many states require Cigna to cover the cost of the external review. Filing should reference the AUA's classification of PDE5 inhibitors as standard-of-care, first-line therapy 6.

Vardenafil Quantity Limits on Cigna Plans

Cigna imposes quantity limits on all PDE5 inhibitors. The standard allowance is 6 to 12 tablets per 30-day period, depending on plan design. Some plans restrict coverage to 6 tablets per month, reflecting the assumption that ED medication is used on-demand rather than daily.

The on-demand dosing of vardenafil was validated in key trials using 5 mg, 10 mg, and 20 mg doses taken approximately 60 minutes before sexual activity 1. The recommended starting dose is 10 mg, which may be adjusted to 20 mg or decreased to 5 mg based on efficacy and tolerability 3. If your prescriber can document that a higher monthly quantity is medically necessary (for example, a patient in a new relationship or undergoing penile rehabilitation after prostatectomy), a quantity limit exception can be submitted alongside the PA.

Post-prostatectomy penile rehabilitation is one clinical scenario where higher quantities have published support. Montorsi et al. demonstrated that early, regular PDE5 inhibitor use following nerve-sparing radical prostatectomy improved return of spontaneous erections at 12 months compared with on-demand use 12.

Using Manufacturer Savings Cards with Cigna

Manufacturer copay cards exist for brand Levitra and Staxyn, though availability has fluctuated as the market shifted toward generics. If a savings card is active, Cigna commercial plans generally permit its use at the point of sale. The card reduces your copay at the pharmacy counter, and the manufacturer pays the difference to the pharmacy.

There is one major caveat. Cigna plans that use copay accumulator or copay maximizer programs may not apply the manufacturer's payment toward your annual deductible or out-of-pocket maximum 13. Under an accumulator program, the savings card offsets your copay, but the amount the manufacturer pays does not count toward your plan's cost-sharing thresholds. Once the card's annual benefit is exhausted, you face the full cost.

Ask your Cigna plan administrator whether your plan uses a copay accumulator before relying on a savings card as a long-term cost strategy. For most patients, generic vardenafil at $30 to $60 per month without a savings card is more predictable than brand Levitra with a savings card subject to accumulator clawback.

Vardenafil Safety Profile and Drug Interactions Relevant to Coverage

Cigna's PA reviewers occasionally cite safety concerns when denying vardenafil. Understanding the drug's interaction profile strengthens your appeal.

Vardenafil is absolutely contraindicated with nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe hypotension 3. Alpha-blocker co-administration requires careful dose separation. The FDA label recommends that vardenafil dosing begin at 5 mg when used with stable alpha-blocker therapy. A pharmacokinetic study confirmed that tamsulosin 0.4 mg daily combined with vardenafil 10 mg produced no clinically significant additional blood pressure reduction compared with either drug alone 14.

QT prolongation is a class-specific concern with vardenafil. The FDA label includes a warning that vardenafil can prolong the QTc interval at supratherapeutic doses (80 mg), and patients taking Class IA or Class III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol) should avoid vardenafil 3. At therapeutic doses of 10 mg and 20 mg, a thorough QT study found mean QTcF increases of 4 to 6 ms, below the regulatory threshold of concern 15.

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) substantially increase vardenafil plasma levels. When ketoconazole 200 mg was administered with vardenafil 5 mg, the AUC increased 10-fold 3. Cigna reviewers may flag this interaction, but the clinical solution is dose reduction to 5 mg rather than therapeutic substitution, a point worth making in any appeal letter.

Cigna Medicare Advantage and Marketplace Plan Differences

Coverage varies sharply between Cigna's commercial, Medicare Advantage, and ACA marketplace products. Medicare Part D plans have historically excluded ED medications under the standard benefit, a restriction dating to the Medicare Modernization Act of 2003 16. Some Cigna Medicare Advantage plans offer supplemental ED drug coverage as an enhanced benefit, but this varies by region and plan year.

ACA marketplace plans sold by Cigna follow essential health benefit requirements set by each state's benchmark plan. Most state benchmarks do not mandate ED drug coverage, giving Cigna discretion to exclude or restrict PDE5 inhibitors. If your marketplace plan excludes vardenafil, no appeal pathway exists because the exclusion is written into the plan contract.

For men with ED related to diabetes, cardiovascular disease, or post-surgical nerve damage, the strongest coverage argument links vardenafil to treatment of a recognized chronic condition. The AUA's 2018 guideline explicitly addresses ED as a marker for cardiovascular risk, citing data from Thompson et al. showing that ED predicted cardiovascular events with a hazard ratio of 1.45 (95% CI 1.25-1.69) in the Prostate Cancer Prevention Trial 17.

Cost-Reduction Strategies Beyond Insurance

If Cigna denies coverage or your out-of-pocket cost remains high, several options exist. Generic vardenafil from a certified online pharmacy typically costs $2 to $5 per tablet. GoodRx and similar discount aggregators frequently bring the retail price below insurance copays.

Telehealth platforms including HealthRX offer vardenafil at transparent pricing without insurance billing, eliminating the PA process entirely. For patients who value privacy or speed over insurance savings, the cash-pay route may be the better fit. A 2021 survey found that 42% of men prescribed ED medications preferred cash-pay options due to insurance hassles and coverage restrictions 18.

Pill splitting is another FDA-acknowledged strategy for cost reduction. A 20 mg vardenafil tablet split in half yields two 10 mg doses at the price of one tablet, though the FDA advises confirming with your pharmacist that the specific tablet formulation scores evenly 5. Staxyn ODT tablets cannot be split and must be used whole.

Your prescriber can request a 90-day supply through Cigna's mail-order pharmacy (Express Scripts), which typically carries a lower per-tablet cost than three consecutive 30-day retail fills. The 2024 Cigna mail-order copay for a Tier 2 generic is often 2.0 to 2.5 times the 30-day copay for a 90-day supply, saving roughly 17-33% per tablet.